Log in or Sign up for Free to view tailored content for your specialty!
Wound Management News
Exclusive interview on 2025 physician fee schedule cuts leads November dermatology news
An in-depth interview about the effects of the CMS’s 2025 physician fee schedule on patient access topped Healio Dermatology’s most-read articles of November, with FDA news also garnering attention.
VIDEO: Repeat exposure to mesh glue dressing may increase allergic contact dermatitis risk
DALLAS — In this video from the American Association of Hip and Knee Surgeons Annual Meeting, Robert A. Burnett, MD, discussed results that showed repeat mesh glue dressing exposure yielded a fivefold increased risk of allergic dermatitis.
Q&A: Cuts to 2025 physician fee schedule yield ‘catastrophic’ impacts to patient access
The CMS finalized cuts to the 2025 physician fee schedule for the fifth year in a row, prompting an urgent call-to-action from the American Academy of Dermatology. HHS, through the CMS, announced the finalization of the 2025 Medicare Physician Fee Schedule.
Log in or Sign up for Free to view tailored content for your specialty!
FDA clears first antimicrobial wound dressing with integrated lidocaine for painful wounds
The FDA has issued a 510(k) clearance to Imbed Biosciences to market Microlyte Ag/Lidocaine for the management of painful skin wounds, the company announced in a press release.
FDA grants BPGbio rare pediatric disease designation for epidermolysis bullosa treatment
The FDA granted rare pediatric disease designation for BPM31510T for the treatment of epidermolysis bullosa, BPGbio announced in a press release.
Catch up with top Healio Dermatology news from August
Celebrity news and nutrition stories led Healio Dermatology’s most-read articles in August.
Ilya Pharma’s investigational treatment receives rare pediatric disease designation
The FDA has issued a rare pediatric disease designation to Ilya Pharma for its topical emilimogene sigulactibac treatment for STING-associated vasculopathy with onset in infancy, according to a press release.
Bromelain-based enzymatic debridement agent rapidly treats venous leg ulcer wounds
A new bromelain-based enzymatic debridement product was effective at rapidly debriding venous leg ulcer wounds without pain, according to this study.
FDA approves pediatric indication for NexoBrid for treatment of thermal burns
The FDA has approved a pediatric indication for NexoBrid for the treatment of deep partial-thickness and full-thickness thermal burns, Vericel Corporation announced in a press release.
Avita, Regenity enter development agreement for wound care product
Avita Medical Inc. has entered into an agreement with Regenity Biosciences to develop and distribute its collagen-based dermal matrix for wound healing, the company announced in a press release.
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read
-
Headline News
Medicare selects 15 drugs for second round of price negotiations, including semaglutide
January 17, 20252 min read -
Headline News
Q&A: Physicians can help patients with respiratory diseases prepare for wildfires
January 17, 20253 min read -
Headline News
‘Now is not the time to lose momentum’ in the fight against STIs
January 10, 20259 min read